Mofebutazone

• Description :

  Mofebutazone, a monophenyl analogue of Phenylbutazone (HY-B0230), is an orally active anti-inflammatory agent. Mofebutazone can be used for research of asthma[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H315, H319, H332, H335

• Target :

  Drug Derivative

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/mofebutazone.html

• Purity :

  98.42

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(C1CCCC)NN(C2=CC=CC=C2)C1=O

• Molecular Formula :

  C13H16N2O2

• Molecular Weight :

  232.28

• Precautions :

  H301, H315, H319, H332, H335

• References & Citations :

  [1]F.T. Delbeke, et al. Determination of mofebutazone and its 4-hydroxy metabolite in plasma and urine by high-performance liquid chromatography. Journal of Chromatography A. Volume 369, 1986, Pages 440-444|[2]Khayyal MT, et al. Tolerability of mofebutazone in asthmatic patients. Int J Clin Pharmacol Res. 1995;15 (4) :145-51.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2210-63-1]